MarketResearchReports.Biz
announces addition of new report"
Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1,
2016 "to
its database.
GlobalData's
clinical trial report, Systemic
Sclerosis (Scleroderma) Global
Clinical Trials Review, H1, 2016" provides an overview of
Systemic Sclerosis (Scleroderma) clinical trials scenario. This
report provides top line data relating to the clinical trials on
Systemic Sclerosis (Scleroderma). Report includes an overview of
trial numbers and their average enrollment in top countries conducted
across the globe. The report offers coverage of disease clinical
trials by region, country (G7 & E7), phase, trial status, end
points status and sponsor type. Report also provides prominent drugs
for in-progress trials (based on number of ongoing trials).
GlobalData Clinical Trial Reports are generated using GlobalDatas
proprietary database - Pharma eTrack Clinical trials database.
Clinical trials are collated from 80+ different clinical trial
registries, conferences, journals, news etc across the globe.
Clinical trials database undergoes periodic update by dynamic
process.
The
report enhances the decision making capabilities and helps to create
an effective counter strategies to gain competitive advantage.
Download Sample copy of this
Report at
Scope
-
The report provides a snapshot of the global clinical trials
landscape
-
Report provides top level data related to the clinical trials by
Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor
Type and End point status
-
The report reviews top companies involved and enlists all trials
(Trial title, Phase, and Status) pertaining to the company
-
The report provides all the unaccomplished trials (Terminated,
Suspended and Withdrawn) with reason for unaccomplishment
-
The Report provides enrollment trends for the past five years
-
Report provides latest news for the past three months
Reasons to buy
-
Assists in formulating key business strategies with regards to
investment
-
Helps in identifying prominent locations for conducting clinical
trials which saves time and cost
-
Provides top level analysis of Global Clinical Trials Market which
helps in identifying key business opportunities
-
Supports understanding of trials count and enrollment trends by
country in global therapeutics market
-
Aids in interpreting the success rates of clinical trials by
providing a comparative scenario of completed and uncompleted
(terminated, suspended or withdrawn) trials
-
Facilitates clinical trial assessment of the indication on a global,
regional and country level
Browse
More PressRelease:
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average
Enrollment by Country 7
Top Five Countries Contributing
to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing
to Clinical Trials in Europe 11
Top Countries Contributing to
Clinical Trials in North America 12
Top Countries Contributing to
Clinical Trials in Middle East and Africa 13
Top Countries Contributing to
Clinical Trials in Central and South America 14
Clinical Trials by G7
Countries: Proportion of Systemic Sclerosis (Scleroderma) to
Immunology Clinical Trials 15
Clinical Trials by Phase in G7
Countries 17
Clinical Trials in G7 Countries
by Trial Status 18
Clinical Trials by E7
Countries: Proportion of Systemic Sclerosis (Scleroderma) to
Immunology Clinical Trials 19
Clinical Trials by Phase in E7
Countries 20
Clinical Trials in E7 Countries
by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status
24
Clinical Trials by End Point
Status 25
Subjects Recruited Over a
Period of Time 26
Clinical Trials by Sponsor Type
27
Prominent Sponsors 28
Top Companies Participating in
Systemic Sclerosis (Scleroderma) Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on
Systemic Sclerosis (Scleroderma) 32
Mar 24, 2016: Cytori provides
Update on Its U.S. Phase III Scleroderma Trial 32
Mar 15, 2016: ProMetic
announces the addition of scleroderma to PBI-4050 targeted
indications 32
Feb 25, 2016: Inventiva
rewarded for its innovative approach with IVA337 at the 4th Systemic
Sclerosis World Congress 33
Feb 22, 2016: Data Reports
Sustained Benefit at Two Years with Single Administration Cytori Cell
Therapy for Scleroderma 33
Feb 10, 2016: Scleroderma Two
Year Data to be Presented at the 4th Systemic Sclerosis World
Congress 34
Jan 28, 2016: IVA337 delivers
significant therapeutic advances in fibrosis, a major public health
challenge 34
Jan 25, 2016: Cytori Update on
Its U.S. Phase III Scleroderma Trial 35
Clinical Trial Profile
Snapshots 36
Appendix 187
Abbreviations 187
Definitions 187
Research Methodology 188
Secondary Research 188
About GlobalData 189
Contact Us 189
Disclaimer 189
Source 190
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment